Gammagard Liquid®
Understanding Gammagard Liquid®
Gammagard Liquid® is an immunoglobulin (IgG) therapy used to treat Primary Immunodeficiency (PI) disordersand Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It provides antibodies to strengthen the immune system, helping reduce infections in PI patients and modulate the immune response in CIDP patients, reducing inflammation and preventing disease progression. Gammagard Liquid® can be administered intravenously (IVIG) or subcutaneously (SCIG) for flexible treatment options.
How Gammagard Liquid® Works:
- Provides essential antibodies to support immune function.
- Helps prevent infections in patients with PI.
- Modulates immune response to reduce inflammation in CIDP.
FDA Approval:
- 1986 – Approved for the treatment of Primary Immunodeficiency (PI)
- Later approved for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
For more information, please visit the Gammagard Liquid® patient website and speak with your healthcare provider to determine if Gammagard Liquid® is the right treatment option for you.
Referral Form: |
WHAT IT TREATS: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Chronic Lymphocytic Lymphoma (CLL)Chronic Spontaneous Urticaria (CSU)Common Variable Immunodeficiency (CVID)Guillain-Barre Syndrome (GBS)Immune Thrombocytopenic Purpura (ITP)Kawasaki Disease (KD)Kidney TransplantMultifocal Motor Neuropathy (MMN)Myasthenia Gravis (MG)Severe Combined Immunodeficiencies (SCID)Wiskott-Aldrich Syndrome (WAS)X-linked Agammaglobulinemia (XLA) |
MANUFACTURER: Takeda Pharmaceutical Company |
CLASS: Immune Globulin (IgG) |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: IV infusion |
|
FREQUENCY: Varies |
Length of infusion: Varies from one hour to several hours depending on the dose |
FOR MORE INFORMATION: |
Related drugs
